Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
LOWER RESPIRATORY TRACT INFECTIONS IN CATS
Reaching beyond empirical therapy

Prerequisites for a clinical diagnosis of feline LRTI

Bacteria, parasites, fungi and viruses cause lower respiratory tract infections (LRTIs) in cats. Most cats with LRTIs have pneumonia (inflammation of the lung parenchyma), although pathology is occasionally limited to the airways.\(^1\,^2\) Viral causes of LRTIs are unlikely to be diagnosed without lung histopathology and specific viral detection techniques. Parasitic, bacterial and fungal LRTIs can be diagnosed by routine investigation of lower respiratory tract disease. However, obtaining a clinical diagnosis of LRTI can be challenging. Historical, clinical, haematologic and radiographic findings known to be compatible with LRTI are often non-specific or are inconsistently present.\(^1\,^3\,^4\) In addition, some cases of LRTI may have concomitant, predisposing respiratory tract or systemic diseases.

Clinical ante-mortem diagnosis of LRTI relies on analysis of all the patient details: signalment, history, physical examination findings, radiography, cytological and microbiological assessment of bronchoalveolar lavage (BAL) fluid or pulmonary fine needle aspirates (FNAs), histopathology (if available) and response to appropriate therapy. As histopathology is rarely available, BAL (and, to a lesser extent, FNA) cytology and microbiology are the mainstays of ante-mortem investigation of LRTI. However, the cytological and microbiological analyses by the laboratory have to be of an excellent standard for these to be of high diagnostic yield. In addition, for the laboratory to achieve optimal results, high quality samples and appropriate requests from clinicians are essential. Only the veterinarian handling the case can make a diagnosis of LRTI.

Key studies to date on feline LRTIs

There have been three detailed retrospective studies on feline LRTIs: one from Switzerland by Bart et al (2000; 245 cats),\(^2\) one from the USA by Macdonald et al (2003; 39 cats)\(^1\) and one from Australia by Foster et al (2004; 21 cats).\(^3\) The American\(^1\) and Swiss\(^2\) studies both analysed LRTIs that were histologically confirmed at necropsy. Of the two, only the American study assessed clinical findings in addition to post-mortem findings. The rigid selection criteria in the American study...
ensured accuracy of diagnosis but, by its post-mortem nature, precluded analysis of non-fatal cases. The cases in the Australian study were identified by airway and/or pulmonary cytology and microbiology, in conjunction with clinical assessment, including response to appropriate therapy; histopathological confirmation was only available in a few cases as treatment was effective in most cats.

In addition to these studies, there have been numerous case reports and case series describing specific feline LRTIs.

What do the studies tell us about signalment and clinical signs?

Signalment
No breed predilection has been noted for LRTIs in cats. Foster et al found males were 2.4 times more likely to have LRTIs than females. Interestingly, in a recent retrospective study on fatal feline herpesvirus type 1 (FHV-1)-associated pneumonia, all the cases were male.

Clinical signs
The most common presenting complaint in the Australian study was coughing (76%), and the most common abnormalities detected during physical examination were dyspnoea and/or tachypnoea (67%), and coughing or increased tracheal hypersensitivity (38%).

Of the cats diagnosed at necropsy in the American study, only 8% coughed, indicating that while coughing cats should be investigated for LRTI, lack of coughing does not preclude a differential diagnosis of LRTI. In that same study, 36% of cats lacked any clinical signs referable to the respiratory tract and 41% of cats lacked clinical signs of systemic illness. The most common respiratory tract signs were tachypnoea or dyspnoea (49%) and nasal discharge (21%). Pyrexia was noted in 15% of the cats in the American study and 24% of cats in the Australian study; none of the cats that presented alive with LRTI due to Bordetella bronchiseptica were pyrexic in a study on B bronchiseptica infections.

Thus, pyrexia would appear to be a relatively uncommon finding in LRTIs and normothermia does not rule out LRTI.

Despite differences in selection criteria and their impact on clinical presentation, the studies indicate that cats with LRTIs may not have any signs referable to the respiratory tract and that lack of coughing does not preclude a diagnosis. Cats that do have coughing, dyspnoea or tachypnoea should be investigated for LRTI. Careful physical examination and astute clinical acumen are likely to be required if a diagnosis of LRTI is to be made in an affected cat.

How do the studies help direct laboratory investigation?

Haematology
There has been limited investigation of changes to the erythrogram of cats with LRTIs. Foster et al reported that packed cell volume was normal in 8/12 cats and slightly decreased in 4/12 cats. Leukocytosis and neutrophilia are the most common haematological abnormalities. Leukocytosis and neutrophilia were detected in 8/10 and 9/10 cases, respectively, in the Australian study and 9/18 and 7/18 of cases, respectively, in the American study. Leukopenia, neutropenia and left shifts were uncommon. It is noteworthy that 4/18 cats in the American study had leukocyte counts within the reference intervals, despite the fatal disease outcomes. Eosinophilia was present in 4/10 cats in the Australian study and only one of these had a parasitic LRTI. Other parasitic LRTIs in this study were not accompanied by an eosinophilia. As such, haematology is often of little help in the diagnosis of LRTIs in cats.

Biochemistry
Serum biochemical analysis in clinical cases has been limited but serum biochemistry is unlikely to be of help in the diagnosis of LRTI. Cats with LRTIs may have increased globulin and total protein concentrations.

Radiography
In the Australian study, all lung patterns were represented radiographically and, while 67% of cases had alveolar changes, 81% of cases had a bronchial pattern either alone or in combination with another pattern. A predominantly nodular pattern was noted in the cases of cryptococcosis, toxoplasmosis and mycoplasmal abscess. A range of radiographic patterns was also detected in the American study, and, in 3/13 (23%) cases, there were no radiographic abnormalities. Lack of radiographic abnormalities was also reported in a cat with confirmed cryptococcal LRTI.
Lack of consistent radiographic abnormalities contributes to the difficulties in diagnosing LRTIs in cats.

**Bronchoalveolar lavage**

The gold standard procedure for airway sampling is BAL via bronchoscopy. Collection of airway samples by this method is detailed in numerous texts and papers. Bronchoscopic BAL in cats with respiratory disease has a low rate of serious complications and it is possible that the overall complication rate can be reduced further by premedication with terbutaline.

Bronchoscopic alveolar lavage is not always possible due to lack of availability of equipment or financial or time constraints. Other simple and cheaper non-bronchoscopic methods have been described in the literature and these can be readily used in general practice. The non-bronchoscopic BAL procedure used by one of the authors (SF) is outlined in the box above.

**Transtracheal aspiration**

Transtracheal aspiration (TTA) is rarely used in cats as, firstly, patient restraint can exacerbate respiratory signs and, secondly, airway control and ventilation in response to any bronchoconstriction or exacerbation of respiratory signs are easier under anaesthesia. However, if anaesthesia is contraindicated, then this technique can be used instead of BAL. Care must be taken that patient restraint does not result in exacerbation of respiratory signs. Local anaesthetic must be placed prior to introduction of the catheter through the cricothyroid ligament.

An 18–22 G through-the-needle intravenous catheter is optimal (although rarely available in general practice) as the needle can be withdrawn after catheter placement to minimise tracheal injury. Approximately 0.5 ml/kg of warmed sterile saline is instilled into the catheter and then immediately aspirated to retrieve the lavage fluid. A second flush may be required for adequate sampling.

**Lung fine needle aspiration**

Lung fine needle aspiration may be indicated to investigate lesions identified by thoracic radiography or ultrasonography. The specific approach and procedure chosen depend on the type of lesion (mass lesion versus diffuse disease), lesion location (central versus peripheral) and the clinical status of the patient. Aspiration can be performed either blind (for diffuse disease or discrete peripheral focal lesions) or guided by ultrasound, fluoroscopy or computed tomography (CT).

Lung fine needle aspiration might perhaps be expected to entail a higher risk than BAL. However, a number of studies in dogs and cats using 22–27 G hypodermic or spinal needles for lung or intrathoracic fine needle aspiration have demonstrated no clinically evident complications. Interestingly, when CT monitoring was used after fine needle aspiration or core biopsy with 18–22 G diameter instruments, 43% of cases had pneumothorax, pulmonary haemorrhage or both, despite the lack of clinical manifestations. Not surprisingly, these complications were common when aerated lung was perforated.
In-house BAL cytology

- Place two drops of lavage fluid containing mucus on a microscope slide.
- Examine the unstained wet preparation microscopically for the presence of parasites.
- Prepare multiple air-dried squash preparations of mucus from each lavage specimen and stain with Diff Quik.
- Check for the presence of mucus, oropharyngeal squames, oropharyngeal bacteria, respiratory pathogens, epithelial cells and inflammatory cells.
- Total cell counts are not performed as reference intervals have not been validated for this method of sample collection.
- Choose some representative fields and count the different types of white cells to provide a differential white cell count for the smear.
- Classify inflammation by the predominant cell type (if ≥50%) or describe the inflammation as ‘mixed’ if no cell type predominates.
- If sufficient material is present, examine several smears from each sample.
- If no mucus is present, a centrifugation technique is required for smear preparation as mucus-free samples may contain abnormal cells.
- If bacteria are identified, Gram staining should be performed; acid-fast stains may also be necessary for some bacteria.

Airways in healthy cats are not sterile and this needs to be taken into account when interpreting airway cytology and microbiology.

Cytology

Cytology can be performed on BAL (or TTA) fluid or lung fine needle aspirates (FNAs). Lung FNA cytology is performed as per any tissue aspirate cytology. In contrast, BAL/TTA fluid analysis has not been standardised. Many studies and most commercial laboratories report total cell counts (which can be influenced by the amount of lavage fluid delivered and retrieved) and use cytospin preparations for cytology; cytospin preparations have been shown to be of better quality than manual smearing of pelleted cells after centrifugation, especially when there is a low total cell count. When performing total cell counts and preparing cytocentrifuged smears, mucus is routinely excluded from the analytic material. However, many of the cells in the BAL fluid are trapped within the mucus strands and not performing direct smears of mucus can result in failure to detect *Aelurostrongylus abstrusus*.

When BAL fluid is collected as described earlier, the practitioner can prepare smears in-house and perform cytology (see box below).

Reporting of differential white cell counts from airway samples is also not standardised. In two feline studies with similar smear preparation, BAL cytology was classified by the predominant inflammatory cell type, if greater than or equal to 50% of the total, or described as mixed, if no cell type predominated. In both studies epithelial cells were not considered in the calculation of relative cell counts, which is consistent with the recommendations of the American Thoracic Society for reporting cell counts in humans.

In cats with LRTIs, cytology performed by the method detailed revealed neutrophilia in all but one. The normal lower airway response to pulmonary bacterial or protozoal infection would appear to be neutrophilic unless there is concurrent immunosuppression. None of the cats with confirmed parasitic infections had an eosinophilic BAL, although other factors may have influenced this – the presence of concurrent salmonellosis in two and feline immunodeficiency virus (FIV) infection in one. Bacteria consistent with the culture results should be observed cytologically in bacterial LRTIs, except in cases of mycoplasmosis; mycobacteria may also be difficult to find cytologically. Mycoplasmas do not usually take up Diff Quik or Gram stain, although small Gram-negative stained ‘flecks’ have occasionally been observed in cytological preparations of BAL fluid from which mycoplasmas were cultured (P Martin, unpublished data).

One small study of feline respiratory cases (only 1/11 with histologically recognised LRTI) demonstrated that BAL fluid cytopathology performed on cytocentrifuged samples does not always correlate with the type of pulmonary disease identified on histopathology. However, histopathology correlated reasonably well with cytology in another study in which a number of cats had inflammatory lower respiratory tract lesions. While one cat with feline infectious peritonitis in this study had normal BAL cytology, which was not representative, cytology in three other cats (one with toxoplasmosis, two with focal bronchitis) was more sensitive than histopathology. The authors concluded that cytological specimens appear more sensitive for the detection of microscopic focal lesions and *Toxoplasma gondii* tachyzoites, but that lesions confined to the interstitium may not be detected in bronchial washings.
The bacteria reported as occurring in low numbers (< 2 x 10^3 colony forming units/ml) in the airways of healthy cats include *Escherichia coli* and species of *Pasteurella, Pseudomonas, Staphylococcus, Streptococcus* and *Micrococcus*. Anaerobic bacteria and mycoplasmas have not been isolated from the lower airways of healthy cats.27,28

The most common bacteria causing feline LRTIs in the three retrospective studies of LRTIs were *B bronchiseptica*, *Pasteurella* species, *Mycoplasma* species, *Streptococcus* species and *E coli*. Other agents identified as causing infectious pneumonia in these studies were other bacteria (including mycobacteria, *Salmonella typhimurium*, *Pseudomonas* species, anaerobes), viruses (herpesvirus, coronavirus), lungworm (*A abstrusus, Eucoleus aerophilus*), protozoa (*T gondii*) and fungi (*Cryptococcus* species, *Candida albicans, Mucor* species, *Aspergillus* species).1–3 Various other aetiological agents have also been identified in case reports and small case series, and described in textbooks.

**Parasitology**
Faecal flotation and faecal analysis by the Baermann technique should be routinely performed in cats with possible LRTIs. Other diagnostic tests for lungworm detection are also available (see later).

**Histopathology**
Lung histopathology is occasionally performed ante-mortem. Samples can be obtained via ultrasound- or CT-guided core biopsy or surgical excision (thoracoscopy or thoracotomy).

**Bacterial LRTIs**

**Mycoplasmas**
Mycoplasmas are the smallest free-living, self-replicating microorganisms and have no cell wall.29 They are represented in the natural mucosal flora of cats but are not normally present in the lower airways.27,28 Both the Swiss2 and Australian3 LRTI studies demonstrated the importance of mycoplasmas in feline LRTIs. Mycoplasmas are known pulmonary pathogens in other species and have been recorded as causing pyothorax, pneumonia (Fig 1), LRTIs and pulmonary abscessation in cats.2,3,30–40 *Mycoplasma felis* has also been shown to directly induce pneumonia in two healthy kittens after experimental inoculation.41

Despite this, mycoplasmal LRTIs are often considered to be a consequence of pre-existing pulmonary diseases such as FBD. It is possible that feline mycoplasmas may be aetiological agents rather than secondary in FBD, causing serious pathology and resulting in ongoing inflammatory bronchial disease and airway hyperresponsiveness similar to *Mycoplasma pneumoniae* in humans.3,37,42–44

**FIG 1 Radiographs of a cat with a mycoplasmal LRTI.**
(a) Right lateral thoracic radiograph showing consolidation in the cranial lung lobe area. (b) Ventrodorsal thoracic radiograph showing consolidation of the left cranial lung lobe. (c) Right lateral thoracic radiograph after 6 weeks of therapy. Note the improved aeration of the cranial lung lobe. Reprinted from Foster et al (1998),36 with permission of John Wiley and Sons, publisher of the Australian Veterinary Journal

It is possible that feline mycoplasmas may be aetiological agents rather than secondary in feline bronchial disease, causing serious pathology and resulting in ongoing inflammatory bronchial disease and airway hyperresponsiveness, similar to *Mycoplasma pneumoniae* in humans.
Diagnosis

Mycoplasmas do not take up Diff Quik or Gram stain, a finding usually attributed to their lack of a cell wall.\(^2\) Culture of mycoplasmas is difficult as they may not survive transport to a laboratory and usually require specific culture media. Diagnosis of mycoplasmosis in the Australian LRTI study was only possible because there was no transport delay and mycoplasmas were cultured from the peptone-enriched blood agar plates used (Fig 2).\(^3\)

Specific polymerase chain reaction (PCR) testing is likely to improve the sensitivity of diagnosis, as it has in human medicine. However, in practice, mycoplasmal LRTI will remain a difficult diagnosis as neither mycoplasmal culture nor mycoplasmal PCR testing is performed routinely. Clinicians need to make specific provisions (such as specialised transport swabs) and laboratory requests when investigating possible mycoplasmal LRTI. Treatment trials are often a more attractive alternative.

Treatment

Treatment of mycoplasmal infections in veterinary medicine is usually empirical. Antibiotic susceptibility profiles are not available for feline mycoplasmal isolates. Mycoplasmas are generally reported to be sensitive to macrolides (erythromycin, clarithromycin, tylosin), fluoroquinolones (enrofloxacin, ciprofloxacin, pradofloxacin), tetracyclines, chloramphenicol and gentamicin. Enrofloxacin may not be as effective as doxycycline,\(^3\) but pradofloxacin has demonstrated similar efficacy to doxycycline for upper respiratory tract (URT) infections caused by mycoplasmas.\(^41\)

Doxycycline would appear to be an appropriate and affordable initial choice of antibiotic for empirical therapy of feline LRTIs. The monohydrate preparation of doxycycline available in Australia (VibraVet; Pfizer) has not been reported to cause the oesophagitis and oesophageal strictures that have been noted in other countries with hydrochloride preparations. If using doxycycline, however, it is recommended that each dose be followed by a water or food swallow.\(^52\)

Fig 2 Heavy growth of mycoplasma isolated aerobically on sheep blood agar from a feline BAL sample after 3–4 days of incubation. Note the small lucent colonies buried in the agar and surrounded by zones of haemolysis

Key Points: Mycoplasmas

- Mycoplasmas do not take up Diff Quik or Gram stain and do not respond to \(\beta\)-lactam antibiotics.
- Specific transport swabs and culture media are required for diagnosis if PCR is not available.
- Mycoplasmal infections result in neutrophilic BAL cytology with no demonstrable bacteria.
- Treatment trials with doxycycline or fluoroquinolones may be required if clinical evidence is suggestive of mycoplasmosis and specific testing is not available.
- Mycoplasmas are one of the ‘hot topics’ in human asthma medicine. Their role in feline asthma has yet to be explored.
It is probably worth treating all cats with lower respiratory tract disease with an appropriate antibiotic for mycoplasmas while awaiting results of cytology and culture. 

It is probably worth treating all cats with lower respiratory tract disease with an appropriate antibiotic for mycoplasmas while awaiting results of cytology and culture. Additionally, if FBD/asthma is suspected and the cat is stable enough to allow trial antibiotic treatment, then this should also be considered prior to immunosuppressive or anti-inflammatory medication. It does need to be noted, however, that some antimicrobials have beneficial effects on airway inflammation unrelated to antimycoplasmal activity. 

The duration of treatment required is not known. Mycoplasmal species that infect animals and humans are able to induce chronic disease states in which clearance of the organism is extremely difficult. Intracellular localisation, immunomodulatory effects and surface antigen variations may all contribute to this process. Prior allergic sensitisation of the lungs could potentially also result in delayed organism clearance, as it does with *M pneumoniae* in experimental murine models. Treatment of mycoplasmal URT disease in cats for 42 days has been recommended, as PCR-positive results after 28 days have been demonstrated. Given that chronic persistent infection has been documented in humans, that some cases of mycoplasmal LRTI have been reported to have recurrent doxycycline-responsive coughing or need continuous treatment, and the finding that 42 days may be required for treating feline URT mycoplasmal infections, it may be prudent to treat mycoplasmal LRTIs with doxycycline (5 mg/kg PO q12h) for a minimum of 6 weeks.

*Bordetella bronchiseptica*

*Bordetella bronchiseptica* is a primary respiratory pathogen in cats. Naturally occurring *B bronchiseptica* infection may cause URT signs (sneezing, ocular nasal discharge) or LRT signs (coughing, severe dyspnoea, cyanosis and even death due to bronchopneumonia). Young kittens appear to be most susceptible to disease due to *B bronchiseptica* and fatal bronchopneumonia has been reported in kittens. Lower respiratory tract infection due to *B bronchiseptica* has also been reported in adult cats and fatal bronchopneumonia was reported in 10 cats, which were presumably adults as they were recorded as ‘cats’ and not ‘kittens’. Bronchopneumonia, which was unresponsive to appropriate and intensive therapy, also occurred recently in another adult cat (D Foster, unpublished data; Fig 3). Virology studies have not always been performed to assess concurrent viral respiratory tract infection in field studies. Concurrent feline calicivirus (FCV) infection was demonstrated in some cases and concurrent feline herpesvirus (FHV) in one. Concurrent feline panleukopenia was associated in another report. Regardless, *B bronchiseptica* appeared to be a significant contributing cause to bronchopneumonia and death in these cats.

Antibiotic treatment early in the course of the disease is recommended. Antibiotic susceptibility for this organism indicates that it is usually resistant to penicillin, cephalosporins and ampicillin, and sensitive to a wide range of antibiotics including tetracyclines, enrofloxacin, amoxicillin–clavulanate, chloramphenicol and gentamicin. Although most antimicrobials are able to attain concentrations in the lung parenchyma comparable to drug concentrations in the serum, concentrations achieved in the airways and bronchial secretions may be significantly lower. This is particularly relevant to the treatment of LRTIs due to *B bronchiseptica*, as this bacterium attaches to the cilia on the surface of the tracheobronchial epithelium (Fig 3). The β-lactam drugs, in particular, have low distribution into respiratory secretions and so cannot be recommended for the treatment of *B bronchiseptica*. Trimethoprim-sulphonamides was used successfully in four cats with bronchopneumonia but a high level of resistance to trimethoprim-sulphonamide was detected in one study. Enrofloxacin was used unsuccessfully in one cat, which then responded to trimethoprim-sulphonamide and successfully in another.

Thus, the current recommended drugs for the treatment of bronchopneumonia due to *B bronchiseptica* are doxycycline, trimethoprim-sulphonamide and fluoroquinolones.
**Streptococcus species**

Beta-haemolytic streptococci are commensal microflora of the skin, pharynx, URT and genital tract of cats. Infections with Lancefield group G streptococci in kittens and occasionally in adult cats are known to result in pneumonia associated with pleuritis and cervical lymphadenitis. Fasciitis and myositis, and toxic shock-like syndrome. In the American retrospective LRTI study, β-haemolytic Streptococcus species were the most common bacterial cause of LRTIs (29% of cases). *Streptococcus* species were also a major cause of deaths in the Swiss retrospective LRTI study, the majority of which were in kittens less than 12 weeks old. By contrast, *Streptococcus* species were not identified as a cause of LRTI in the predominantly ante-mortem, adult cat study from Australia, so it is possible that pneumonia due to *Streptococcus* species may be severe and rapidly fatal and/or occur predominantly in kittens.

The majority of β-haemolytic streptococcal infections in cats are caused by Lancefield group G streptococci, usually *S. canis*. However, recently, an outbreak of respiratory disease due to *S. equi* (Lancefield group C) in a large shelter caused approximately 10% mortality. Clinical disease in these cats was characterised by copious purulent nasal discharge and coughing, progressing to sinusitis, dyspnoea, signs of pneumonia and death. *Streptococcus pneumoniae* (Lancefield group A) was reported to cause a moderate interstitial pneumonia in a kitten that died with fasciitis and myositis. *Streptococcus suis* has also been isolated from pneumatic lungs in a 2-week-old kitten and a 2-year-old cat.

Lancefield group G streptococci of cats have been uniformly sensitive to penicillin, which has been regarded as the drug of choice. Procaine and benzathine penicillin (long-acting penicillin) have been used both in the treatment of cases and prophylactically in cats. Penicillin doses are usually provided in terms of units. The mg/kg conversions for the various preparations of penicillin G [eg, penicillin G potassium and sodium, penicillin G procaine, penicillin G benzathine] are provided in many editions of Plumb’s Veterinary Drug Handbook.

In humans, clindamycin is regarded as the drug of choice in necrotising fasciitis or toxic shock streptococcal syndromes. Clindamycin is also reported to be valuable in the treatment of streptococcal infections in cats. Fluoroquinolones are not recommended for treating streptococcal infections.

**Escherichia coli**

Extraintestinal pathogenic *E. coli* (ExPEC) has been reported to cause respiratory disease outbreaks in cats. Thirteen cats from an animal shelter developed acute respiratory disease and died from acute necrotising pneumonia in a week in one such outbreak. Fatal pneumonia occurred in three kittens in an outbreak in another shelter. In addition to the feline impact, such outbreaks also have zoonotic potential.

Comparing the three retrospective LRTI studies, *E. coli* was isolated in 2/39 (5%) total cases (2/21 bacterial cases) in the American study and 21/245 (9%) cases in the Swiss study, of which 16 were septicaemic and most occurred in kittens less than 12 weeks old. *Escherichia coli* was not identified in the Australian study of predominantly ante-mortem cases, although a fatal case of pneumonia due to *E. coli* and *A. abstrusus* was diagnosed in a kitten subsequent to the study (Fig 4). Lower respiratory tract infections due to *E. coli*, while relatively uncommon, would thus appear to be associated with high mortality, especially in kittens.

**Pasteurella species**

*Pasteurella* species are part of the microflora of the nasopharynx and airways of healthy cats. Not surprisingly, these bacteria are one of the more common species to be isolated from cats with LRTIs. It is likely that concurrent viral infections and other stresses leading to impaired defence mechanisms result in pneumonia due to *Pasteurella* species. These bacteria are usually susceptible to the aminopenicillanic derivatives.

**Salmonella species**

Pneumonia due to *Salmonella* species can occur in association with systemic salmonellosis or as a localised LRTI. Concurrent infection with *A. abstrusus* has been reported in two cases. While LRTIs due to *Salmonella* species would appear to be uncommon, it is worth noting that at least one adult cat with LRTI due to salmonellosis (and concurrent *A. abstrusus* and *Pseudomonas* species infections) presented with signs typical of FBD/asthma: chronic coughing, dyspnoea and tachypnoea in an otherwise apparently healthy cat. Another adult cat had no clinical history of respiratory disease, rather a chronic history of inappetence, lethargy and recent weight loss. If corticosteroids had been used for non-specific symptomatic treatment in either cat, then there may have been very serious consequences.
Practitioners in the mid- and far-western USA must consider plague as a differential diagnosis in any cat with pneumonia.

**Yersinia pestis**
Plague exists in every continent apart from Australia. The areas most frequently associated with plague foci are adjacent to deserts and have semi-arid, cooler climates, although there are foci in areas such as Southeast Asia, which are unlikely to have that profile. Practitioners in the mid- and far-western USA must consider plague as a differential diagnosis in any cat with pneumonia.

Pneumonic plague in cats can develop secondarily to haematogenous or lymphatic spread from bubonic or septicaemic forms. However, in a large case series, 8/12 cats with pneumonia appeared to have primary pneumonic plague. Cats have also been thought to be responsible for primary pneumonic plague in people who have had contact with them. Although infection with *Y pestis* is relatively rare, its importance relates to its zoonotic potential and the fact that untreated pneumonic plague in cats and humans is uniformly fatal. Gentamicin and tetracyclines are considered effective antibiotics against *Y pestis* in humans. In cats, tetracyclines (with doxycycline preferred) are used primarily for uncomplicated cases, for the bubonic form and, prophylactically, for in-contact cats. The recovery rate in a large cases series of cats treated with tetracyclines was 95%, but administration of tetracyclines has been reported to have been associated with...
of these, only M. thermoresistibile have been reported as caus-
ing localised respiratory tract infections. 90–93

R. equi has occasionally been reported to cause disease, including LRTI, in cats. 97

A recent study comparing BAL examination, faecal sedimentation–flotation, histological examination and the Baermann technique (minced lung tissue and faeces) demonstrated that the Baermann technique on faeces was the most sensitive test for the detection of A. abstrusus infection. 21 The combination of stereomicroscopic and cytological examination of BAL fluid improved the sensitivity of BAL diagnosis in that study, and a direct smear of any gross mucus was recommended in addition to standard cytopsin preparations. 21

Rhodococcus equi

Usually considered an equine pathogen, Rhodococcus equi has occasionally been reported to cause disease, including LRTI, in cats. 97

Lower respiratory tract infection was reported in four kittens from unrelated, in-contact litters in a breeding cattery. One kitten had a moist productive cough and subsequently died. Necropsy revealed suppurrative bronchopneumonia and a pure growth of R. equi was cultured from the lungs. The remaining kittens were successfully treated with doxycycline with or without erythromycin. 97

Phylogenetic LRTIs

Aelurostrongylus abstrusus

A recent study in semi-feral Australian cats demonstrated the prevalence of A. abstrusus to be 13.8% 21 a study in Italy demonstrated a prevalence of 24%. 102 The prevalence in pet cats is likely to be considerably lower but LRTIs due to A. abstrusus may well be underdiagnosed as infection is usually self-limiting, often asymptomatic, may mimic FBD/asthma and responds reasonably well to symptomatic treatment for FBD/asthma. While not usually considered a major clinical problem, A. abstrusus can cause severe signs of lower respiratory tract disease, including dyspnoea and coughing. It may also predispose to infections with enteric bacteria such as Salmonella species and E. coli (Fig 4), with migrating lungworm larvae possibly acting as carriers for intestinal bacteria. 277

Diagnosis

Diagnosis of A. abstrusus infection can be difficult. 121,103 Both BAL (Fig 6) 3 and lung FNA cytology have been used for diagnosis. 104 A recent study comparing BAL examination, faecal sedimentation–flotation, histological examination and the Baermann technique (minced lung tissue and faeces) demonstrated that the Baermann technique on faeces was the most sensitive test for the detection of A. abstrusus infection. 21 The combination of stereomicroscopic and cytological examination of BAL fluid improved the sensitivity of BAL diagnosis in that study, and a direct smear of any gross mucus was recommended in addition to standard cytopsin preparations. 21

However, faecal analysis by the Baermann technique has limitations: it is time consuming (24–36 h), requires well-trained microscopists and is not able to diagnose infections during the prepatent period and when larvae are not being shed. 103 Another faecal analysis method, the FLOTAC technique, is considerably easier although requires specific equipment. A study performed on faeces from a single infected cat indicated that this technique yielded significantly more sensitive results. 104

While not usually considered a major clinical problem, A. abstrusus can cause severe signs of lower respiratory tract disease, including dyspnoea and coughing.
larvae per gram than the Baermann technique.\textsuperscript{105} Recently, a nested PCR test performed on pharyngeal swabs has also been shown to have excellent sensitivity (96.6\%) and specificity (100\%),\textsuperscript{106} and thus would appear to be the diagnostic test of choice if available.

**Treatment**

A single dose of ivermectin (400 µg/kg SC) is often recommended for treatment of *A. abstrusus* infections.\textsuperscript{4,86} This recommendation is made because a single dose of oral ivermectin at 300 µg/kg was ineffective in two cats\textsuperscript{107} and ivermectin administered at 200 µg/kg SC proved ineffective in another cat.\textsuperscript{108} A dose of 400 µg/kg SC 2.5 weeks later in this particular cat was successful.\textsuperscript{108} While the high dose appeared effective, it may be that two doses were in fact required for complete resolution, as two doses of abamectin 300 µg/kg SC, 2 weeks apart, have been successful.\textsuperscript{3}

There is one report of a cat treated successfully with a single 400 µg/kg SC dose of ivermectin,\textsuperscript{109} but treatment failures with this dose have also been reported.\textsuperscript{108,110} While a single dose of ivermectin 400 µg/kg SC may result in elimination of infection or decreased larval output and improved clinical signs, it cannot be recommended unless the response is monitored with Baermann faecal analysis (or a test of similar sensitivity). Two doses are required if empirical treatment is employed. It is worth noting that use of ivermectin or abamectin is ‘off-label’ and care needs to be taken in kittens. The bioavailability of ivermectin may be lower in cats than dogs and thus parenteral administration is preferable to oral.\textsuperscript{3}

Oral fenbendazole (50 mg/kg q24h for 10–20 days) is another possible treatment.\textsuperscript{110,111} The usual licensed dose (50 mg/kg q24 h for 3 days) does not clear infections in all cats.\textsuperscript{112,113}

Topical therapy for this parasite has been reported.\textsuperscript{110,112–114} Imidacloprid/moxidectin (Advocate; Bayer), given once, proved 100% effective in 12 cats,\textsuperscript{112} which makes this the treatment of choice in most countries, being available, registered for cats, easy to administer and efficacious. Emodepside/praziquantel (Profender; Bayer) was 99% effective.\textsuperscript{113} Topical selamectin has only been effective in 2/4 cats in which its use has been reported.\textsuperscript{110,114}

**Eucoleus aerophilus**

*Eucoleus aerophilus* (previously *Capillaria aerophila*) has a worldwide distribution. In Australia, a prevalence of 3–5% has been reported,\textsuperscript{115,116} and a recent study demonstrated a similar prevalence (5.5\%) in Italy.\textsuperscript{117} The prevalence of clinical disease due to *E. aerophilus* has previously been assumed to be low,\textsuperscript{4,86} but 8/11 cats in one study had respiratory signs (most commonly, general respiratory distress, dry cough, wheezing and sneezing).\textsuperscript{117} These findings indicate that *E. aerophilus* is of clinical importance and should be included in the differential diagnosis of lower respiratory tract diseases in cats. In addition, it should be noted that this parasite has zoonotic potential: human capillariasis can cause severe clinical signs and mimic bronchial carcinoma.\textsuperscript{118}

Diagnosis of infection with *E. aerophilus* should be straightforward as the ova are passed in the faeces and routine faecal flotation is adequate for detection. However, the double-operculated ova of *E. aerophilus* (Fig 7) may be mistaken for *Trichuris* species when found in faecal preparations.

Two doses of abamectin (Avomec; Merial) 300 µg/kg SC, 2 weeks apart, were used successfully for the treatment of *E. aerophilus* in a case report.\textsuperscript{119} Fenbendazole, at 50 mg/kg PO for 10–14 days, has also been suggested.\textsuperscript{111} Treatment with topical Advocate (Bayer) or Profender (Bayer), as for *A. abstrusus*, may be worth considering but the efficacy of these topical agents has not been reported for infections due to *E. aerophilus*.

**KEY POINTS: LUNGWORM**

- Lungworm infections due to *A. abstrusus* and *E. aerophilus* may be overlooked in cats.
- Specific detection techniques may be required for diagnosis of infection due to *A. abstrusus*.
- Topical imidacloprid/moxidectin (Advocate; Bayer) would appear to be the treatment of choice for *A. abstrusus* infection.
- Single-dose ivermectin therapy is not recommended for treatment of *A. abstrusus* infection.

*E. aerophilus* is of clinical importance and has zoonotic potential. The double-operculated ova may be mistaken for *Trichuris* species.
Toxoplasma gondii

Cats are definitive hosts for the coccidian parasite *T. gondii*. The lung appears to be a target organ in both primary and reactivated toxoplasmosis in cats. Serology may be consistent with infection but does not provide a definitive diagnosis. Diagnosis is possible by BAL cytology in cats, but lung FNA cytology and lung biopsy evaluation may fail to identify *T. gondii*. Immunohistochemistry and tissue culture have been recommended for lung biopsies and BAL specimens from human patients with acquired immunodeficiency syndrome (AIDS).

Assessment of the efficacy of clindamycin in clinical cases is difficult. One study reported it to be efficacious; however, the selection criteria for that study included response to appropriate treatment or histopathological confirmation and the only case with definite histological confirmation died without treatment. Pooling several papers and one unpublished case (K Briscoe, personal communication, Fig 8) of confirmed pulmonary toxoplasmosis, only one cat with mild clinical signs (but significant pulmonary pathology) responded well to clindamycin treatment alone. Another cat with a 2-week history of respiratory signs and tachypnoea and dyspnoea on presentation, due to pulmonary toxoplasmosis, survived 3 months after being given clindamycin as the sole treatment, before dying (no necropsy performed). However, two cats treated solely with clindamycin died. Three cats treated with clindamycin and trimethoprim/sulphonamide or sulfamethoxazole also died, as did one treated with clindamycin and doxycycline. One cat treated with clindamycin plus pyrimethamine for 16 days and then trimethoprim/sulphonamide and pyrimethamine for 26 days survived long-term, as has a recent unpublished case treated with clindamycin and pyrimethamine (K Briscoe, personal communication, Fig 8). Thus, in 10 cases of pulmonary toxoplasmosis, only one survived long-term with sole clindamycin therapy and no cats survived with clindamycin and sulphonamide treatment. The only clindamycin combination therapy that was successful was clindamycin and pyrimethamine.

Definitive diagnosis is usually by BAL cytology or post-mortem histopathology. Pulmonary toxoplasmosis is increasingly identified as a complication of ciclosporin therapy in cats. Sole clindamycin therapy is not recommended for pulmonary toxoplasmosis. Clindamycin (12.5 mg/kg q24h PO) and pyrimethamine (0.25–0.5 mg/kg q12h PO) combination therapy may be useful to treat pulmonary toxoplasmosis in cats immunosuppressed by ciclosporin.
Clindamycin (12.5 mg/kg q24h PO) and pyrimethamine (0.25–0.5 mg/kg q12h PO) may be a better option, especially in cats immunosuppressed with ciclosporin. Clindamycin should always be followed by food or a water swallow as its use has been associated with oesophageal injury.140

Treatment with sulphonamides would also appear to be ineffective. Dubey and Carpenter reported that 17/17 cases of toxoplasmosis (signalment, presentation details and organ systems affected not specified) died despite sulphonamide treatment: 12 died or were euthanased within 30 h and the other five lived from 2–13 days.122 Eight of these cats were treated concurrently with pyrimethamine. Pyrimethamine alone has marked in vitro activity against *T gondii* whereas sulfadiazine has not, but pyrimethamine and sulfadiazine have synergistic activity.137 Pyrimethamine has greater efficacy than trimethoprim when used in combination with a sulphonamide but can cause bone marrow suppression in cats.141 Regardless, it is probably worth considering this drug in the initial acute phases of disease.

Doxycycline, minocycline, azithromycin, clarithromycin and various combinations with pyrimethamine and sulphonamides are also outlined as possible treatment protocols.141 Azithromycin is reported to have a delayed action of onset similar to clindamycin.137 It is perhaps also worth considering the use of triazines such as toltrazuril, which have shown promise in the treatment of equine protozoal myeloencephalitis.142 Diclazuril and pyrimethamine in mice with experimentally induced acute toxoplasmosis had a synergistic effect on survival.143 and toltrazuril has been shown to be effective against the intestinal developmental stages of *T gondii* and reasonably effective against extra-intestinal stages of *T gondii* in cats.144

**Paragonimus species**

Trematodes in the genus *Paragonimus* develop to maturity in the lungs. While *P kellicotti* is the most commonly reported pathogen of the genus in cats, there are at least 28 species and all are probably capable of developing within the cat.145 Typically, they are found in cysts within the lungs. Each cyst may contain 1–10 flukes.145 They can cause serious disease in the infected host and a number of these trematodes, including *P westermani*, cause serious disease in people.145 Natural infection in cats with paragonimiasis in parts of Asia may be as prevalent as 45–59%.146,147

*Paragonimus kellicotti* is distributed throughout the Mississippi and Great Lakes drainage systems of North America.145 Aquatic snails and crayfish are required intermediate hosts. Infections may be subclinical or cause coughing (occasionally haemoptysis) or dyspnoea, due to inflammation, pneumothorax or secondary bacterial pneumonia. Wheezing in cats may mimic FBD/asthma. Thoracic radiographs demonstrate air-filled cysts or tissue masses averaging 1 cm, usually involving the caudal lung lobes. Diagnosis can be made by BAL or faecal analysis (sedimentation recommended and multiple faecal samples may be required). Treatment involves praziquantel (at 25 mg/kg q8h PO for 3 days) or fenbendazole (at 25–50 mg/kg q12h PO for 10–14 days).4

*Paragonimus westermani* is found in Southeast Asia. In cats with heavy natural infections, there is extensive injury to the lung parenchyma (atelectasis and fibrosis) and the pleura (thickening and fibrosis).145 Successful treatment of a natural infection with praziquantel 100 mg/kg daily for 2 days has been reported.148

*Paragonimus mexicanus*, found in Mexico and Central and South America, causes similar signs to *P kellicotti*.145 *Paragonimus heterotremus*, found in China, Thailand and Laos, has been reported to have caused the death of a cat that had a natural infection with 13 flukes.145

*Paragonimus miyazakii* occurs naturally in cats in Japan150 and is reported to cause similar clinical signs to *P westermani*.145 *Paragonimus skrjabini* occurs naturally in cats in China147 but clinical signs do not appear to have been described.145 Experimentally cats have also been infected with many species including *P ueterobilateralis*,151 *P heterotremus*,152 *P yunnanensis*,153 *P iloitsuenensis*154 and *P veocularis*.155

**Cytauxzoon felis**

*Cytauxzoon felis*, a regionally common, tick-borne parasite, causes an interstitial pneumonia characterised by neutrophilic infiltrates and pulmonary oedema. Respiratory distress is seen in affected cats.156 Prevention via ectoparasite control and confinement indoors in the tick season is recommended as treatment attempts have met with limited success and disease is often fatal.157 Most success in treatments has been with the carbanilide compounds, diminazene or imidocarb.157

**Dirofilaria immitis**

*Dirofilaria immitis* (heartworm) is a cardiovascular parasite that may cause coughing and dyspnoea in cats due to proliferative and inflammatory lesions in the pulmonary arteries, bronchioles and lung parenchyma (heartworm associated respiratory disease).158 Ante-mortem diagnosis is difficult due to the low number of adult worms generally present in cats. Heartworm antigen and microfilaria testing has low sensitivity and diagnosis usually requires a high degree of clinical suspicion, serology, radiography and echocardiography.
Fungal LRTIs

Fungal causes of feline LRTIs include Cryptococcus species, Histoplasma capsulatum, Sporothrix schenckii, Aspergillus species, Mucor species, Candida species, Coccioidoides immitis, Blastomyces dermatitidis, Ochrononsc gallopavorum, Paecilomyces lilacinus and Cladophialaphora bantiana. Siamese and Abyssinian cats appear to have an increased prevalence of cryptococcosis161,165 and, possibly, histoplasmosis. Siamese cats also featured prominently in an early description of blastomycosis cases. Abyssinian and Havana brown cats have been reported to be over-represented for blastomyocosis.

Ante-mortem clinical diagnosis of fungal LRTIs usually involves thoracic radiographs, cytology and culture. Careful cytology is required to demonstrate organisms within macrophages. Pulmonary FNA cytology is often required and fungal culture increases the likelihood of organism identification. Detection of capsular antigen in serum by the latex agglutination procedure is a sensitive diagnostic test for cryptococcosis. The test, however, is rarely included as a screening test for LRTIs and is more usually performed after diagnosis, in order to monitor treatment.

Cryptococcus species

No cases of cryptococcal pneumonia were identified in the Swiss LRTI study. In the Australian study, cryptococcal LRTI was only identified in a single FIV-positive cat which had the hallmarks of AIDS-like disease: opportunistic infections and, terminally, neoplasia. However, in the American study, 5/39 LRTI cases had a diagnosis of cryptococcal pneumonia.

The lungs are considered the primary site of infection for cryptococcosis in humans. Pulmonary cryptococcal infections have been reported to be quite rare in cats, although 29% of cases reviewed in one study of cryptococcosis had thoracic radiographic abnormalities and 38% had pulmonary lesions at necropsy. Pulmonary involvement in one cat was identified only by BAL (thoracic radiographs were normal). It is possible that pulmonary cryptococcosis may be underestimated if BAL or lung histopathology is not performed.

Itraconazole has been used successfully for the treatment of pulmonary cryptococcosis, but monitoring of antigen titres is essential to document disease resolution as with other manifestations of feline cryptococcosis.

Other fungi

Blastomycosis and coccidiomycosis rarely cause respiratory disease in cats. Cats, however, are very susceptible to histoplasmosis, most cats presenting with disseminated disease. Signs are usually non-specific but 38–93% of cats have been reported to have respiratory tract signs. While coughing is uncommon, over half of affected cats have dyspnoea, tachypnoea and abnormal lung sounds. Itraconazole is the treatment of choice for histoplasmosis.

Viral LRTIs

Obtaining an ante-mortem diagnosis of viral pneumonia is rare in clinical practice as histopathology and specific viral tests are required.

Feline calicivirus

Feline calicivirus is usually only reported to cause interstitial pneumonia in cats under experimental conditions. However, outbreaks of naturally occurring pneumonia have also occurred. In one such outbreak, six kittens died and another six kittens, all with URT signs, were euthanased. The six euthanased kittens had histopathological evidence of pneumonia: multifocal interstitial pneumonia in five and bronchopneumonia in one that had concurrent B bronchiseptica infection. Bronchointerstitial pneumonia can also occur with virulent systemic FCV infections.

Feline herpesvirus

Feline herpesvirus is a rare cause of pneumonia and is usually reported in kittens or debilitated animals. However, a recent retrospective study on FHV-induced pneumonia demonstrated fatal fibrinoncrotising pneumonia and severe necrosis of the bronchial and bronchiolar epithelium in four young adult and mature adult cats, none of which had concurrent disease identified or recorded; three were from shelters but one was from a private household or breeding cattery (combined category for the study). The two oldest cats (aged 3 and 8 years), one from a shelter and one from a private household/breeding cattery, had sudden death as their only history. It may be that FHV is an underdiagnosed cause of pneumonia in older cats as few mature cats with sudden death have post-mortem histopathology performed.

Treatment with specific antiherpetic viral medication could be considered if LRTI due to FHV was suspected. Famciclovir (62.5 mg q12h to 125 mg q8h PO) has recently been associated with improvement in some adult cats with FHV-related disease, but there are no reports of its use in LRTI due to FHV. Adjunctive therapies with lysine (250 mg q12h PO) and interferon alpha may also be worth considering.
Cowpox
Cowpox virus infection in cats is rare and usually leads to cutaneous lesions. Until recently, cases of pulmonary infection and pneumonia have been associated with fatality. Johnson et al, however, recently described a cat that recovered from a necrotising bronchopneumonia in which both cowpox virus and FHV were confirmed using histopathology, scanning electron microscopy and isolation of poxvirus from skin lesions. Such investigations would be rare on live cats so it is possible that resolving pneumonia due to cowpox may have been underreported.

Consolidated lung lobes with mild pleural effusion would appear to be a radiographic feature and should prompt consideration of this disease in regions in which this infection is known to occur. Cowpox is zoonotic and transmission to a human has occurred in at least one instance of feline cowpox pneumonia.

Avian influenza virus A (H5N1)
Avian influenza virus A (H5N1) was reported to have caused the death of 14 cats in a household in Thailand, and also caused lethal bronchointerstitial pneumonia in three cats with concurrent A abstrusus infection in Germany. Outdoor cats in contact with wild birds infected with avian influenza are at risk of lethal infection. Detailed articles on feline infection, prevention and management have been published.

Swine-origin influenza A virus (H1N1)
Swine-origin influenza has also been reported in cats. Two cats from Oregon died with moderate to severe necrotising bronchointerstitial pneumonia after H1N1 infections. The cats lived in separate households, 99 km apart. Humans in both households were assumed or proven to be infected with H1N1. One of the households had five additional cats, four of which had signs of respiratory disease but recovered (one was negative for H1N1 on a nasal swab) and one of which was unaffected. Transmission of pandemic 2009 (H1N1) influenza virus from human to cat was also recently implicated in the case of an indoor domestic cat that recovered from clinical disease. Polymerase chain reaction testing on a

Treatment of LRTIs – some general considerations

Perform appropriate diagnostics
Due to the diversity of causes of feline LRTIs, empirical therapy in cats with signs of lower respiratory tract disease is not recommended and appropriate cytology, parasitology and microbiology should be performed in all cases.

Consider the drug characteristics
When treating bacterial LRTIs it is important to consider not only the organism, but also the drug characteristics. Although most antimicrobials are able to attain concentrations in the lung parenchyma comparable with drug concentrations in the serum, concentrations in the airways and bronchial secretions may be significantly lower. Beta-lactams are hydrophilic and are poorly distributed in respiratory secretions and phagocytic cells. Aminoglycosides are inactivated in inflammatory environments after penetration into bronchial secretions and have a low degree of lipid solubility.

Thus, neither class is recommended for treating bronchial infections such as Erhlichia. Fluoroquinolones achieve high levels of distribution in respiratory tissues and intracellularly, as do the macrolides and chloramphenicol. Metronidazole also achieves a high distribution into bronchial secretions. Tetracyclines are lipophilic and tend to cross the blood-bronchus barrier reasonably well, especially doxycycline.

Provide supportive therapy if required
Supportive therapy may be required. Intravenous fluids may aid in maintaining euvoelaemia and airway hydration. Caution must be exercised with high volume fluids in cases of severe pneumonia as the blood-alveolar barrier may be compromised. Oxygen supplementation should be provided if the SpO2 is less than 94% or if the PaO2 is less than 80 mmHg. Methods of administering oxygen include oxygen cages, nasal catheters and flow-by delivery. Severe hypoxaemia may require mechanical ventilation. Use of bronchodilators such as inhaled salbutamol, oral or parenteral terbutaline or oral theophylline is controversial, but bronchodilation does seem helpful in some cases of feline LRTI.

Lung lobectomy
Lung lobectomy is occasionally indicated for treatment when pneumonia fails to resolve with appropriate antimicrobial therapy. Residual infection in a single lobe may be related to an underlying physical problem such as a bronchial foreign body, abscess or tumour.
BAL sample was positive for H1N1 in the cat. Retrospective testing of the family members, two of three of whom had influenza-like signs prior to the cat’s illness, was unsuccessful.

**Other viruses**

The paramyxoviruses, equine morbillivirus (*Hendra* virus) and *Nipah* virus, have been reported to cause pneumonia experimentally in cats, though neither are primarily feline viruses.

Feline infectious peritonitis due to feline coronaviral infections may involve the pulmonary parenchyma. Neither FIV nor FeLV directly cause overt signs of lower respiratory tract disease, although FIV has been reported to cause interstitial pneumonitis in infected cats and alter BAL cytology in cats experimentally infected with FIV for at least 8 months. Feline foamy virus also caused histopathological lesions in the lungs after experimental infection, but did not result in clinical signs.

**Acknowledgements**

The authors express appreciation to Drs Julia Beatty, Katherine Briscoe and Katrina Bosward from the Faculty of Veterinary Science, University of Sydney, Australia, and Dr Darren Foster from the Small Animal Specialist Hospital, North Ryde, Australia, for generously providing excellent case material and photos.

**References**

1. Macdonald ES, Norris CR, Berghaus RB, Griffey SM. Clinico-pathologic and radiographic features and etiologic agents in cats with histologically confirmed infectious pneumonia: 39 cases (1991–2000). *J Am Vet Med Assoc* 2003; 223: 1142–50.
2. Bart M, Gussetti E, Zurbriggen A, Pospisilh A, Schiller I. Feline infectious pneumonia: a short literature review and a retrospective immunohistological study on the involvement of *Chlamydia* spp and distemper virus. *Vet J* 2000; 159: 220–30.
3. Foster SF, Martin P, Allan GS, Barnes VR, Malik R. Lower respiratory tract infections in cats: 21 cases (1995–2000). *J Feline Med Surg* 2004; 6: 167–80.
4. Hawkins EC. Pulmonary parenchymal diseases. In: Ettinger SJ, Feldman EC, eds. *Textbook of veterinary internal medicine*. 5th edn. Philadelphia: Saunders, 2000: 1061–91.
5. Chvala-Mannsberger S, Bagó Z, Weissenböck H. Occurrence, morphological characterization and antigen localization of felid herpesvirus-induced pneumonia in cats: a retrospective study (2000–2006). *J Comp Pathol* 2009; 141: 163–69.
6. Welsh RD. *Bordetella bronchiseptica* infections in cats. *J Am Anim Hosp Assoc* 1996; 32: 153–58.
7. Hamilton TA, Hawkins EC, DeNicola DB. Bronchoalveolar lavage and tracheal wash to determine lung involvement in a cat with cryptococcosis. *J Am Vet Med Assoc* 1991; 198: 655–56.
8. Hawkins EC. Bronchoalveolar lavage. In: King LG, ed. *Textbook of respiratory disease in dogs and cats*. St Louis: Saunders, 2004: 118–28.
9. Johnson LR, Drazenovich TL. Flexible bronchoscopy and bronchoalveolar lavage in 68 cats (2001–2006). *J Vet Intern Med* 2007; 21: 219–225.
10. Foster SF, Martin P, Braddock JA, Malik R. A retrospective analysis of feline bronchoalveolar lavage cytology and microbiology (1995–2000). *J Feline Med Surg* 2004; 6: 189–98.
11. Foster D. Diagnosis and management of chronic coughing in cats. *In Practice* 1998; 20: 261–67.
12. Sparks A, Wotton P, Brown P. Tracheobronchial washing in the dog and cat. In *Practice* 1997; 19: 257–59.
13. McCarthy G, Quinn PJ. The development of lavage procedures for the upper and lower respiratory tract of the cat. *Irish Vet J* 1986; 40: 6–9.
14. Moise NS, Blue J. Bronchial washings in the cat: procedure and cytologic evaluation. *Compend Contin Educ Pract Vet* 1983; 5: 621–27.
15. Syring RS. Tracheal washes. In: King LG, ed. *Textbook of respiratory disease in dogs and cats*. St Louis: Saunders, 2004: 128–34.
16. Wood EF, O’Brien RT, Young KM. Ultrasound-guided fine-needle aspiration of focal parenchymal lesions of the lung in dogs and cats. *J Vet Intern Med* 1998; 12: 338–42.
17. Rechle JK, Wisner ER. Non-cardiac thoracic ultrasound in 75 feline and canine patients. *Vet Radiol Ultrasound* 2000; 41: 154–62.
18. DeBerry JD, Norris CR, Samii VF, Griffey SM, Almy FS. Correlation between fine-needle aspiration cytology and histopathology of the lung in dogs and cats. *J Am Anim Hosp Assoc* 2002; 38: 327–36.
19. Zekas LJ, Crawford JT, O’Brien RT. Computed tomography-guided fine-needle aspiration and tissue-core biopsy of intrathoracic lesions in thirty dogs and cats. *Vet Radiol Ultrasound* 2005; 46: 200–4.
20. Dehard S, Benaerts F, Peeters D, et al. Comparison of bronchoalveolar lavage cytopsin analysis and smears in dogs and cats. *J Am Anim Hosp Assoc* 2008; 44: 285–94.
21. Lacorcia L, Gasser RB, Anderson GA, Beveridge I. Comparison of bronchoalveolar lavage fluid examination and other diagnostic techniques with the Baermann technique for detection of naturally occurring *Aelurostrongylus abstrusus* infection in cats. *J Am Vet Med Assoc* 2008; 232: 365–74.
American Thoracic Society. Clinical role of bronchoalveolar lavage in adults with pulmonary disease. *Am Rev Respir Dis* 1990; 142: 481–86.

22 M. Moise NS, Wiedenkeller D, Yeager AE, Blue JT, Scarlett J. Clinical, radiographic, and bronchial cytologic features of cats with bronchial disease: 65 cases (1980–1986). *J Am Vet Med Assoc* 1989; 194: 1467–73.

23 Barth RM, Metcalfe SS, Krokenberger MB, et al. Disseminated *Mycobacterium avium* infection in young cats: overrepresentation of Abyssinian cats. *J Feline Med Surg* 2006; 8: 23–44.

24 Norris CR, Griffeys SM, Sami VF, Christopher MM, Mellem MS. Thoracic radiography, bronchoalveolar lavage cytology, and pulmonary parenchymal histopathology: a comparison of diagnostic results in 11 cats. *J Am Anim Hosp Assoc* 2002; 38: 337–45.

25 Pedrid PA, Feldman BF, Funk K, Samitz EM, Reil D, Cross CE. Greenlee PG, Roszel JF. Feline bronchial cytology: histologic/cytologic correlation in 22 cats. *Vet Pathol* 1984; 21: 308–15.

26 Padrí PA, Feldman BF, Funk K, Samitz EM, Reil D, Cross CE. Cyto logic, microbiologic, and biochemical analysis of bronchoalveolar lavage fluid obtained from 24 healthy cats. *Am J Vet Res* 1991; 52: 1300–7.

27 Randolph JF, Moise NS, Scarlett JM, Shin SJ, Blue JT, Corbett JR. Prevalence of mycoplasmal and ureaplasmal recovery from tracheobronchial lavages and of mycoplasmal recovery from pharyngeal swab specimens in cats with or without pulmonary disease. *Am J Vet Res* 1993; 54: 897–900.

28 Waites KB, Talbot GV. *Mycoplasma pneumoniae* and its role as a human pathogen. *Clin Microbiol Rev* 2004; 17: 697–728.

29 Switzer WP. The genus *Mycoplasma*. In: Merchant I, Pack B, ed. Veterinary bacteriology and virology. 7th edn. Ames: Iowa State University Press, 1967: 531–48.

30 Wong WT, Noor F. Pyothorax in the cat – a report of two cases of *Kajian Vetrinar* 1984; 16: 15–17.

31 Crisp MS, Birchard SJ, Lawrence AE, Fingeroth J. Pulmonary abscess caused by a *Mycoplasma* sp in a cat. *J Am Vet Med Assoc* 1987; 191: 340–42.

32 Pedersen NC. Mycoplasmal infections. In: Holzworth J, ed. *Diseases of the cat*. Philadelphia: Saunders, 1987: 308–19.

33 Moise NS, Dietze AE. Bronchopulmonary diseases. In: Sherding RG, ed. The cat: diseases and management. New York: Churchill Livingston, 1989: 809.

34 Malik R, Love DN, Hunt GB, Canfield PJ, Taylor V. Pyothorax associated with a *Mycoplasma* species in a kitten. *J Small Anim Pract* 1991; 32: 31–34.

35 Foster SF, Barres V, Martin P, Malik R. Pneumonia associated with *Mycoplasma* spp in three cats. *Aust Vet J* 1998; 76: 640–64.

36 Chandler JC, Lappin MR. Mycoplasmal respiratory infections in small animals: 17 cases (1988–1999). *J Am Anim Hosp Assoc* 2002; 38: 111–19.

37 Chelliah M, Gurturk K. Pyothorax associated with a *Mycoplasma* sp and *Arcanobacterium pyogenes* in a kitten. *Aust Vet J* 2002; 80: 344–45.

38 Trow AV, Rozanski EA, Tidwell AS. Primary mycoplasmal pneumonia associated with reversible respiratory failure in a cat. *J Feline Med Surg* 2008; 10: 398–402.

39 Swift S, Dukes-McEwan J, Fonfarra S, Loureiro JF, Burrow R. Aetiology and outcome in 90 cats presenting with dyspnoea in a referral population. *J Small Anim Pract* 2009; 50: 466–73.

40 Tan RJS. Susceptibility of kittens to *Mycoplasma felis* infection. *Jpn J Exp Med* 1974; 41: 235–40.

41 Sabato AR, Martin AJ, Marmion BP, Kok TW, Cooper DM. *Mycoplasma pneumoniae*: acute illness, antibiotics and subsequent pulmonary function. *Arch Dis Child* 1984; 59: 1034–37.

42 Waites KB, Balish MF, Atkinson TP. New insights into the pathogenesis of *Mycoplasma pneumoniae* infections. *Future Microbiol* 2008; 3: 635–48.

43 Rollins DR, Beuther DA, Martin RJ. Update on infection and antibiotics in asthma. *Curr Allergy Asthma Rep* 2010; 10: 67–73.

44 Johnston SL, Martin RJ. *Chlamydia pneumoniae* and *Mycoplasma pneumoniae*: a role in asthma pathogenesis? *Am J Respir Crit Care Med* 2005; 172: 1078–89.

45 Petrovsky T. *Mycoplasma pneumoniae* infection and post-infection asthma. *Med J Aust* 1990; 152: 391.

46 Yano T, Ichikawa Y, Komatsu S, Arai S, Oizumi K. Association of *Mycoplasma pneumoniae* antigen with initial onset of bronchial asthma. *Am J Respir Crit Care Med* 1994; 149: 1348–53.

47 Sutherland ER, Brandorff JM, Martin RJ. Atypical bacterial pneumonia and asthma risk. *J Asthma* 2004; 41: 863–68.

48 Sutherland ER, Martin RJ. Asthma and atypical bacterial infection. *Chest* 2007; 132: 1962–66.

49 Wu Q, Martin RJ, LaFasto S, et al. Toll-like receptor 2 down-regulation in established mouse allergic lungs contributes to decreased mycoplasma clearance. *Am J Respir Crit Care Med* 2008; 177: 270–29.

50 Hartmann AD, Helps CR, Lappin MR, Werckenthin C, Hartmann K. Efficacy of pradofloxacin in cats with feline upper respiratory tract disease due to *Chlamyphila pneumoniae* or *Mycoplasma infections*. *J Vet Intern Med* 2008; 22: 44–52.

51 German AJ, Cannon MJ, Dye C, et al. Oesophageal strictures in cats associated with doxycycline therapy. *J Feline Med Surg* 2005; 7: 33–41.

52 Gaskell RM, Dawson S, Radford A. Feline respiratory disease. In: Green CE, ed. Infectious diseases of the dog and cat. St Louis: Saunders Elsevier, 2006: 145–54.

53 Willoughby K, Dawson S, Jones RC, et al. Isolation of*B bronchiseptica* from kittens with pneumonia in a breeding cattery. *Vet Rec* 1991; 129: 407–8.

54 Fisk SK, Soave OA. *Bordetella bronchiseptica* in laboratory cats from central California. *Lab Anim Sci* 1973; 23: 33–35.

55 Little S. *Bordetella bronchiseptica* infection in a cat. *Fel Pract* 2000; 28: 12–15.

56 Snyder SB, Fisk SK, Fox JG, Soave OA. Respiratory tract disease associated with *Bordetella bronchiseptica* infection in cats. *J Am Vet Med Assoc* 1973; 163: 293–94.

57 Turqoust SE, Oslund E. Calicivirus outbreak with high mortality in a Missouri feline colony. *J Vet Diagn Invest* 1997; 9: 195–98.

58 Foley JE, Rand C, Bannasch MJ, Norris CR, Milan J. Molecular epidemiology of feline bordetellosis in two animal shelters in California, USA. *Prev Vet Med* 2002; 54: 141–56.

59 Olsen JD. Rational antibiotic therapy for respiratory disorders in dogs and cats. *Vet Clin North Am Small Anim Pract* 2000; 30: 1337–55.

60 Speakman AJ, Dawson S, Binns SH, Gaskell CJ, Hart CA, Gaskell RM. *Bordetella bronchiseptica* infection in the cat. *J Small Anim Pract* 1999; 40: 252–56.

61 Speakman AJ, Binns SH, Osborn AM, et al. Characterization of antibiotic resistance plasmids from *Bordetella bronchiseptica*. *J Antimicrob Chemother* 1997; 40: 811–16.

62 Greene CE, Prescott JF. Streptococcal and other Gram-positive bacterial infections. In: Greene CE, ed. Infectious diseases of the dog and cat. 3rd edn. St Louis: Saunders Elsevier, 2006: 302–16.

63 Blanchard P, Wilson D. Group G streptococcal infections in kittens. In: Kirk RW, ed. Current veterinary therapy X. Philadelphia: WB Saunders, 1989: 1891–93.
Wu CC, Kiupel M, Raymond JT, de Gortari MJ, Lin TL. Group G streptococcal infection in a cat colony. J Vet Diagn Invest 1999; 11: 174–77.

Sura R, Hinckley LS, Risatti GR, Smyth JA. Fatal necrotising fasciitis and myositis in a cat associated with Streptococcus canis. Vet Rec 2008; 162: 450–53.

Zhang S, Wilson F, Pace L. Streptococcus pneumoniae-associated cellulitis in a two-month-old domestic shorthair kitten. J Vet Diagn Invest 2006; 18: 221–24.

Taillfer M, Dunn M. Group G streptococcal toxic shock-like syndrome in three cats. J Am Anim Hosp Assoc 2004; 40: 418–22.

Blum S, Elad D, Zukin N, et al. Outbreak of Streptococcus equi subsp zooepidemicus infections in cats. Vet Microbiol 2010; 144: 236–39.

Devriese LA, Haesebrouck F. Streptococcus suis infections in horses and cats. Vet Rec 1992; 130: 380.

Tillman PC, Dodson ND, Indiveri M. Group G streptococcal epizootic in a closed cat colony. J Clin Microbiol 1982; 16: 1057–60.

Sura R, Van Kuizingen HJ, DebRoy C, et al. Extrapleural pathogenic Escherichia coli-induced acute necrotizing pneumonia in cats. Zoonoses Public Health 2007; 54: 307–13.

Highland MA, Byrne BA, Debroy C, Samitz EM, Peterson TS, Oslund KL. Extrapleural pathogenic Escherichia coli-induced pneumonia in three kittens and feline prevalence in a clinically healthy cohort population. J Vet Diagn Invest 2009; 21: 609–15.

Greene CE, Norris Reiner C. Bacterial respiratory infections. In: Greene CE, ed. Infectious diseases of the dog and cat. 3rd edn. St Louis: Saunders Elsevier, 2010: 1096–119.

Widman JT, de Gortari MJ, Lin TL. Group G streptococcal infection in a cat colony. J Vet Diagn Invest 1999; 11: 174–77.

Sura R, Hinckley LS, Risatti GR, Smyth JA. Fatal necrotising fasciitis and myositis in a cat associated with Streptococcus canis. Vet Rec 2008; 162: 450–53.

Zhang S, Wilson F, Pace L. Streptococcus pneumoniae-associated cellulitis in a two-month-old domestic shorthair kitten. J Vet Diagn Invest 2006; 18: 221–24.

Taillfer M, Dunn M. Group G streptococcal toxic shock-like syndrome in three cats. J Am Anim Hosp Assoc 2004; 40: 418–22.

Blum S, Elad D, Zukin N, et al. Outbreak of Streptococcus equi subsp zooepidemicus infections in cats. Vet Microbiol 2010; 144: 236–39.

Devriese LA, Haesebrouck F. Streptococcus suis infections in horses and cats. Vet Rec 1992; 130: 380.

Tillman PC, Dodson ND, Indiveri M. Group G streptococcal epizootic in a closed cat colony. J Clin Microbiol 1982; 16: 1057–60.

Sura R, Van Kuizingen HJ, DebRoy C, et al. Extrapleural pathogenic Escherichia coli-induced acute necrotizing pneumonia in cats. Zoonoses Public Health 2007; 54: 307–13.

Highland MA, Byrne BA, Debroy C, Samitz EM, Peterson TS, Oslund KL. Extrapleural pathogenic Escherichia coli-induced pneumonia in three kittens and feline prevalence in a clinically healthy cohort population. J Vet Diagn Invest 2009; 21: 609–15.

Greene CE, Norris Reiner C. Bacterial respiratory infections. In: Greene CE, ed. Infectious diseases of the dog and cat. 3rd edn. St Louis: Saunders Elsevier, 2010: 1096–119.

Widman JT, de Gortari MJ, Lin TL. Group G streptococcal infection in a cat colony. J Vet Diagn Invest 1999; 11: 174–77.

Sura R, Hinckley LS, Risatti GR, Smyth JA. Fatal necrotising fasciitis and myositis in a cat associated with Streptococcus canis. Vet Rec 2008; 162: 450–53.

Zhang S, Wilson F, Pace L. Streptococcus pneumoniae-associated cellulitis in a two-month-old domestic shorthair kitten. J Vet Diagn Invest 2006; 18: 221–24.

Taillfer M, Dunn M. Group G streptococcal toxic shock-like syndrome in three cats. J Am Anim Hosp Assoc 2004; 40: 418–22.

Blum S, Elad D, Zukin N, et al. Outbreak of Streptococcus equi subsp zooepidemicus infections in cats. Vet Microbiol 2010; 144: 236–39.

Devriese LA, Haesebrouck F. Streptococcus suis infections in horses and cats. Vet Rec 1992; 130: 380.

Tillman PC, Dodson ND, Indiveri M. Group G streptococcal epizootic in a closed cat colony. J Clin Microbiol 1982; 16: 1057–60.

Sura R, Van Kuizingen HJ, DebRoy C, et al. Extrapleural pathogenic Escherichia coli-induced acute necrotizing pneumonia in cats. Zoonoses Public Health 2007; 54: 307–13.

Highland MA, Byrne BA, Debroy C, Samitz EM, Peterson TS, Oslund KL. Extrapleural pathogenic Escherichia coli-induced pneumonia in three kittens and feline prevalence in a clinically healthy cohort population. J Vet Diagn Invest 2009; 21: 609–15.

Greene CE, Norris Reiner C. Bacterial respiratory infections. In: Greene CE, ed. Infectious diseases of the dog and cat. 3rd edn. St Louis: Saunders Elsevier, 2010: 1096–119.
J Clin Microbiol 2008; 46: 1811–17.

107 Blagburn BL, Hendrix CM, Lindsay DS, Vaughan JL. Anthelmintic efficacy of ivermectin in naturally parasitized cats. Am J Vet Res 1987; 48: 670–72.

108 Kirkpatrick CE, Megella C. Use of ivermectin in treatment of *Aelurostrongylus abstrusus* and *Toxocara* cat infections in a cat. J Am Vet Med Assoc 1987; 190: 1309–10.

109 Burgu A, Sarimehmetoglu O. *Aelurostrongylus abstrusus* infection in two cats. Vet Rec 2004; 154: 602–4.

110 Grandi G, Calvi LE, Venco L, et al. *Aelurostrongylus abstrusus* (cat lungworm) infection in five cats from Italy. Vet Parasitol 2005; 134: 177–82.

111 Sherding RG. Parasites of the lung. In: King LG, ed. Textbook of respiratory disease in dogs and cats. St Louis: Saunders; 2004: 548–59.

112 Traversa D, Di Cesare A, Milillo P, et al. Efficacy and safety of imidacloprid 10%/moxidectin 1% spot-on formulation in the treatment of feline aelurostrongylosis. Parasitol Res 2009; 105 (suppl 1): 555–60.

113 Traversa D, Milillo P, Di Cesare A, et al. Efficacy and safety of emodepside 2.1%/praziquantel 8.6% spot-on formulation in the treatment of feline aelurostrongylosis. Parasitol Res 2009; 105 (suppl 1): S83–S89.

114 Reinhardt S, Ottenjann M, Schunack B, Kohn B. [Lungworm infestation (*Aelurostrongylus abstrusus*) in a cat.] Kleintierpraxis 2004; 49: 239–46. German.

115 Milstein TC, Goldsmith JM. Parasites of feral cats from southern Tasmania and their potential significance. Aust Vet J 1997; 75: 218–19.

116 Holmes PR, Kelly JD. *Capillaria aerophila* in the domestic cat in Australia. Aust Vet J 1973; 49: 472–73.

117 Traversa D, Di Cesare A, Milillo P, Iorio R, Otranto D. Infection by *Eukoeleus aerophilus* in dogs and cats: is another extra-intestinal parasitic nematode of pets emerging in Italy? Res Vet Sci 2009; 87: 270–72.

118 Lalosevic D, Lalosevic V, Klem I, Stanojev-Jovanovic D, Pozio E. Pulmonary capillariasis miming bronchial carcinoma. Am J Trop Med Hyg 2008; 78: 14–16.

119 Barrs VR, Martin P, Nicoll RG, Beatty JA, Malik R. Pulmonary cryptococcus and *Capillaria aerophila* infection in an FIV-positive cat. Aust Vet J 2000; 78: 154–58.

120 Parker GA, Langloss JM, Dubey JP, Hoover EA. Pathogenesis of acute toxoplasmosis in specific-pathogen-free cats. Vet Pathol 1981; 18: 786–803.

121 Feeney DA, Sautter JH, Lees GE. An unusual case of acute disseminated toxoplasmosis in a cat. J Am Anim Hosp Assoc 1981; 17: 311–14.

122 Dubey JP, Carpenter JL. Histologically confirmed chronic toxoplasmosis in cats: 100 cases (1952–1990). J Am Vet Med Assoc 1993; 203: 1556–66.

123 Sardinas JC, Chastain CB, Collins BK, Schmidt D. *Toxoplasma gondii* pneumonia in a cat with incongruous serological test results. J Small Anim Pract 1994; 35: 104–7.

124 Eddlestone SM, Hoskins JD, Hoggood G, Dubey JP. Take the Compendium challenge. [Concurrent *Haemobartonella felis* and *Toxoplasma gondii* infection in a cat.] Compend Contin Educ Pract Vet 1996; 18: 774–79.

125 Foster SF, Charles JA, Canfield PJ, Beatty JA, Martin P. Reactivated toxoplasmosis in a FIV-positive cat. Aust Vet Pract 1998; 28: 159–63.

126 Poitout F, Weiss DJ, Dubey JP. Lung aspirate from a cat with respiratory distress. Vet Clin Pathol 1998; 27: 10, 21–22.

127 Litster AL, Mitchell G, Menrath V. Pulmonary toxoplasmosis in a FIV-negative cat. Aust Vet Pract 1999; 29: 154–58.

128 Bernsteen L, Gregory CR, Aronson LR, Lirtzman RA, Brummer DG. Acute toxoplasmosis following renal transplantation in three cats and a dog. J Am Vet Med Assoc 1999; 215: 1123–26.

129 Brownlee L, Sollon RK. Diagnosis of naturally occurring toxoplasmosis by bronchoalveolar lavage in a cat. J Am Anim Hosp Assoc 2001; 37: 251–55.

130 Last RD, Suzuki Y, Manning T, Lindsay D, Calipeau L, Whitbread TJ. A case of fatal systemic toxoplasmosis in a cat being treated with cyclosporin A for feline atopy. Vet Dermatol 2004; 15: 194–98.

131 Anfray P, Bonetti C, Fabbrini F, Magno S, Mancianti F, Abram F. Feline cutaneous toxoplasmosis: a case report. Vet Dermatol 2005; 16: 131–36.

132 Barrs VR, Martin P, Beatty JA. Antemortem diagnosis and treatment of toxoplasmosis in two cats on cyclosporin therapy. Aust Vet J 2006; 84: 30–35.

133 Derouin F, Sarfati C, Beauvais B, Iliou MC, Dehen L, Lariviere M. Laboratory diagnosis of pulmonary toxoplasmosis in patients with acquired immunodeficiency syndrome. J Clin Microbiol 1989; 27: 1661–63.

134 Nash G, Kerschmann RL, Herndier B, Dubey JP. The pathological manifestations of pulmonary toxoplasmosis in the acquired immunodeficiency syndrome. Hum Pathol 1994; 25: 652–58.

135 Davidson MG, Lappin MR, Rottman JR, et al. Paradoxical effect of clindamycin in experimental, acute toxoplasmosis in cats. Antimicrob Agents Chemother 1996; 40: 1352–59.

136 Pfefferkorn ER, Nothngal RF, Borotz SE. Parasitcidal effect of clindamycin on *Toxoplasma gondii* grown in cultured cells and selection of a drug-resistant mutant. Antimicrob Agents Chemother 1992; 36: 1091–96.

137 Harris C, Salgo MP, Tanowitz HB, Wittner M. In vitro assessment of antimicrobial agents against *Toxoplasma gondii*. J Infect Dis 1988; 157: 14–22.

138 Fichera ME, Bhopale MK, Roos DS. In vitro assays elucidate peculiar kinetics of clindamycin action against *Toxoplasma gondii*. Antimicrob Agents Chemother 1995; 39: 1530–37.

139 Lappin MR, Greene CE, Winston S, Toll SL, Epstein ME. Clinical feline toxoplasmosis. Serologic diagnosis and therapeutic management of 15 cases. J Vet Intern Med 1989; 3: 139–43.

140 Beatty JA, Swift N, Foster DJ, Barrs VR. Suspected clindamycin-associated oesophageal injury in cats: five cases. J Feline Med Surg 2006; 8: 412–419.

141 Dubey JP, Lappin MR. Toxoplasmosis and neosporosis. In: Greene CE, ed. Infectious diseases of the dog and cat. 3rd edn. St Louis: Saunders Elsevier, 2006: 754–75.

142 MacKay RJ, Granstrom DE, Saville WJ, Reed SM. Equine protozoal myeloencephalitis. J Feline Med Surg 2004; 6: 131–36.

143 Lindsay DS, Rippey NS, Blagburn BL. Treatment of acute *Toxoplasma gondii* infections in mice with diclazuril or a combination of diclazuril and pyrimethamine. J Parasitol 1995; 81: 315–18.

144 Haberkorn A. Chemotherapy of human and animal coccidioses: state and perspectives. Parasitol Res 1996; 82: 193–99.

145 Bowman DD, Hendrix CM, Lindsay DS, Barr SC. Trematodes of the lungs. In: Feline clinical parasitology. Iowa: Iowa State University, 2002: 163–78.

146 Ming-Sheng Z, Yan-Xia Z, Ming-Hua S, et al. [Epidemiologic survey of paragonimasis in reservoir region of South-North Water Diversion Project.] Zhongguo Bingyuan Shengwuxue Zazhi 2007; 2: 256, 259. Chinese, English abstract.

147 ChengQuan W, Shaojin Y, Dajun W, et al. [Investigation on the
etiology of *Paragonimiasis skrjabini* in Xingshan County locating the Reservoir Area of Three Gorges. *Zhongguo Bingyuan Shengwuxue Zazhi* 2009; 4: 36–39. Chinese, English abstract.

148 Cao WJ, He LY, Zhong HL, et al. Paragonimusiasis: treatment with praziquantel in 40 human cases and in 1 cat. *Arzneimittel Forschung* 1984; 34: 1203–4.

149 Miyazaki I, Vajrasthira S. Occurrence of the lung fluke *Paragonimus heterotremus* Chen et Hsia 1964, in Thailand. *J Parasitol* 1967; 53: 207.

150 Uga S, Matsumara T, Yamada T, Onishi T, Goto M, Kagei N. [On the natural infection of *Paragonimus* spp in cats in Hyogo Prefecture.] *Ipn J Parasitol* 1983; 32: 333–39. Japanese, English abstract.

151 Voelker J, Sachs R. Morphology of the lung fluke *Paragonimus utoxobilateralis* occurring in Gabon, West Africa. *Trop Med Parasitol* 1985; 36: 210–12.

152 Hu W. [Studies on the life cycle of *Paragonimus heterotremus*.] *Chin J Parasitol Parasit Dis* 1998; 16: 347–52. Chinese, English abstract.

153 Ho LY, Chung HL, Cheng LT, Ts’ao WC, Chao SL. [Further observations on *Paragonimus yanunensis* Ho, Chung et al 1959.] *Acta Zoologica Sinica* 1973; 19: 245–56. Chinese, English abstract.

154 Lee SH, Koo KH, Chai JY, Hong ST, Sohn WM. [Experimental infection of *Paragonimus iloktsuenensis* in albino rats, dogs and cats.] *Korean J Parasitol* 1989; 27: 197–202. Korean.

155 Li YS, Chen YZ, Lin CX, et al. [Occurrence of *Paragonimus vocularis* in Fujian Province.] *Chinese J Parasitol Parasit Dis* 2000; 18: 296–300. Chinese, English abstract.

156 Snider TA, Confer AW, Payton ME. Pulmonary histopathology of *Cytoscozon felis* infections in the cat. *Vet Pathol* 2010; 47: 698–702.

157 Greene CE, Meinkoth J, Kocan AA. *Cytauxzoonosis*. In: Greene CE, ed. *Infectious diseases of the dog and cat*. 3rd edn. St Louis: Saunders Elsevier, 2006: 384–437.

158 Atkins C. Heartworm disease. In: Holzworth J, ed. *Diseases of the dog and cat*. St Louis: Saunders Elsevier, 2010: 1353–80.

159 Norris CR. Fungal pneumonia. In: King LG, ed. *Textbook of veterinary internal medicine*. 7th edn. St Louis: Saunders Elsevier, 2004: 412–21.

160 Holzworth J. Mycotic diseases. In: Holzworth J, ed. *Diseases of the dog and cat*. St Louis: Saunders Elsevier, 2006: 584–98.

161 Love DN, Baker KD. Sudden death in kittens associated with a feline picornavirus. *Aust Vet J* 1972; 48: 643.

162 Pesavento PA, MacLachlan NJ, Dillard-Telm L, Grant CK, Hurley KF. Pathologic, immunohistochemical, and electron microscopic findings in naturally occurring virulent systemic feline calicivirus infection in cats. *Vet Pathol* 2004; 41: 257–63.

163 Love DN. Feline herpesvirus associated with interstitial pneumonia in kittens. *Vet Rec* 1971; 89: 178–181.

164 Malik R, Lessels NS, Webb S, et al. Treatment of feline herpesvirus-1 associated disease in cats with famiclovir and related drugs. *J Feline Med Surg* 2009; 11: 40–48.

165 Hinrichs U, van de Poel H, van den Ingh TS. Necrotizing pneumonia in a cat caused by an orthopox virus. *J Comp Pathol* 1999; 121: 191–96.

166 Schöniger S, Chan DL, Hollinshead M, Humm K, Smith GL, Beard PM. Cowpox virus pneumonia in a domestic cat in Great Britain. *Vet Rec* 2007; 160: 522–23.

167 Schulze C, Alex M, Schirmmeier H, et al. Generalized fatal Cowpox virus infection in a cat with transmission to a human contact case. *Zoonoses Public Health* 2007; 54: 31–37.

168 World Health Organization. Avian influenza A(H5N1) – update 28: reports of infection in domestic cats (Thailand), Situation (human) in Thailand, Situation (poultry) in Japan and China. World Health Organization (WHO) Global Alert and Response (GAR), 20 Feb 2004. www.who.int/csr/don/2004_02_20/en/index.html.

169 Klopfleisch R, Wolf PU, Uhl W, et al. Distribution of lesions and antigen of highly pathogenic avian influenza virus *A/ Swann/Germany/R65/06 (H5N1)* in domestic cats after presumptive infection by wild birds. *Vet Pathol* 2007; 44: 261–68.

170 Marschall J, Hartmann K. Avian influenza A H5N1 infections in cats. *J Feline Med Surg* 2008; 10: 359–65.

171 Shiry E, Addie D, Belák S, et al. H5N1 avian influenza in cats. *J Feline Med Surg* 2009; 11: 615–18.

172 Löhrr CV, DeBess EE, Baker RJ, et al. Pathology and viral antigen distribution of lethal pneumonia in domestic cats due to pandemic (H1N1) 2009 influenza A virus. *Vet Pathol* 2010; 47: 378–86.

173 Sponseller BA, Strait E, Jergens A, et al. Influenza A pandemic (H1N1) 2009 virus infection in domestic cat. *Emerg Inf Dis* 2010; 16: 534–37.

174 Hooper PT, Westbury HA, Russell GM. The lesions of experimental equine morbillivirus disease in cats and guinea pigs. *Vet Pathol* 1997; 34: 323–29.

175 Middleton DJ, Westbury HA, Morriess CJ, et al. Experimental *Nipa* virus infection in pigs and cats. *J Comp Pathol* 2002; 126: 34–36.

176 Cadoré JL, Steiner-Laurent S, Greenland T, Mornex JF, Loine R. Intestinal lung disease in feline immunodeficiency virus (FIV) infected cats. *Res Vet Sci* 1997; 62: 287–88.

177 Hawkins EC, Kennedy-Stoskopf S, Levy JK, et al. Effect of FIV infection on lung inflammatory cell populations recovered from bronchoalveolar lavage. *Vet Immunol Immunopathol* 1996; 51: 21–28.

178 German AC, Harbour DA, Helps CR, Gruffydd-Jones TJ. Is feline foamy virus really apathogenic? *Vet Immunol Immunopathol* 2008; 123: 114–18.

179 Brady CA. Bacterial pneumonia in dogs and cats. In: King LG, ed. *Textbook of respiratory disease in dogs and cats*. St Louis: Saunders, 2004: 412–21.